Abstract: Provided are attenuated protein homodimers or heterodimers, comprising an immunoglobulin antigen binding domain (ABD), an IL-12A (p35) protein, and an IL-12B (p40) protein, among other optional features, and related pharmaceutical compositions and methods of use thereof.

Abstract: Provided are improved antibodies, or antigen-binding fragments thereof, which specifically bind to a denatured human collagen polypeptide at a cryptic collagen epitope (anti-denatured collagen antibodies), and fusion proteins comprising anti-denatured collagen antibodies fused to an effector domain, such as a cytokine or an immunomodulatory antibody.

Abstract: Provided are anti-fibroblast activation protein (FAP) antibodies, and antigen-binding fragments thereof, including those having dual binding specificity for human FAP and human CD276 (B7H3), which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases and others.

Abstract: Provided are activatable proprotein heterodimers comprising at least two separate polypeptide chains, one chain comprising an IL-2 protein fused to an IL-15 binding protein such as IL-15R?, and another chain comprising an IL-15 protein fused to an IL-2 binding protein such as IL-2R?, among other features including binding moieties and cleavable linkers, and related pharmaceutical compositions and methods of use thereof.

Abstract: Provided are activatable proprotein or procytokine homodimers composed of at least two separate polypeptide chains, each chain comprising a binding moiety such as an Fc region, a cytokine, a cytokine receptor, and at least one a cleavable linker, among other optional features, and related pharmaceutical compositions and methods of use thereof.

Abstract: The present disclosure discloses a method and a device for extracting broadband error calibration parameters, and a computer-readable storage medium. The method includes: performing frequency band splitting on link broadband signals of an ultra-wide band system according to a received frequency band index table to generate sub-bands; extracting an amplitude error and a phase error of each sub-band; and iteratively weighting and accumulating, according to the frequency band index table and a preset broadband weight table, the amplitude error and the phase error of each sub-band one by one to an initial amplitude error compensation parameter and an initial phase error compensation parameter respectively, to synthesize and extract broadband error calibration parameters.

Abstract: Provided are a Time-Interleaved Successive Approximation Register Analog-to-Digital Converter, TISAR ADC, and a calibration method thereof. The calibration method for the TISAR ADC may include: sampling an analog signal input into the TISAR ADC to generate a reference digital signal (S130); according to the reference digital signal and output digital signals generated by analog-to-digital conversion sub-modules of the TISAR ADC, obtaining capacitor array calibration parameters and time delay calibration parameters of the analog-to-digital conversion sub-modules; adjusting capacitor arrays of the corresponding analog-to-digital conversion sub-modules according to the capacitor array calibration parameters, respectively; and adjusting time delays of the corresponding analog-to-digital conversion sub-modules according to the time delay calibration parameters, respectively.

Abstract: Provided are activatable proprotein homodimers, comprising at least two separate polypeptide chains, each chain comprising an IL-2 protein variant that has reduced binding affinity to wild-type IL-2R? relative to that of the wild-type IL-2 sequence, a cleavable linker, and an IL-2 binding protein, among other optional features, and related pharmaceutical compositions and methods of use thereof.

Abstract: Precursor tri-specific antibody constructs comprising at least one tumor associated antigen binding domain, a T-cell binding domain, and a regulatory domain having enhanced half-life, are described herein. Further, methods of producing the precursor tri-specific antibody constructs are disclosed. Pharmaceutical compositions comprising the precursor constructs and their uses for treating tumors are also disclosed.

Abstract: The present disclosure discloses a method and a device for extracting broadband error calibration parameters, and a computer-readable storage medium. The method includes: performing frequency band splitting on link broadband signals of an ultra-wide band system according to a received frequency band index table to generate sub-bands; extracting an amplitude error and a phase error of each sub-band; and iteratively weighting and accumulating, according to the frequency band index table and a preset broadband weight table, the amplitude error and the phase error of each sub-band one by one to an initial amplitude error compensation parameter and an initial phase error compensation parameter respectively, to synthesize and extract broadband error calibration parameters.

Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Abstract: The present disclosure provides an anti-fuse, which includes at least one anti-fuse unit. The anti-fuse unit includes: a field-effect transistor, including a substrate, and a first doping region, a second doping region and a gate electrode that are disposed on the substrate; and a first electrode, arranged on the substrate and forming an anti-fuse capacitor with the substrate, the first electrode being connected to the first doping region, and configured to break down the anti-fuse capacitor by voltage adjustment between the second doping region and the substrate and write data to the anti-fuse unit, or configured to detect a current flowing through the second doping region by voltage adjustment for the gate electrode and determine whether to write data to the anti-fuse unit. By using the first electrode and the substrate as a pair of plates of the anti-fuse capacitor, a port of the anti-fuse unit may be omitted.

Abstract: The present invention relates to methods of increasing stability and reducing aggregation in compositions comprising antibody Fc molecules and to composition comprising such molecules. Certain amino acid substitutions in the CH3 domain result in increased stability and reduced aggregation of compositions containing polypeptides comprising a CH3 domain, e.g., an antibody or Fc-fusion protein.

Abstract: The invention relates to monomeric Fc polypeptides and methods of making and using such polypeptides. The polypeptides comprise substitution of one or more hydrophobic interface residues in the CH3 region with a polar amino acid.

Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Abstract: Described herein is an antibody format, which is amenable to bispecific antibody creation. This format is referred to herein as “Domain Insertion Immunoglobulin G” or “(Di-IgG)”. The Di-IgG molecules are capable of specifically binding two different antigens simultaneously, show high level recombinant expression, and are sufficiently aggregation-free to be amenable to commercial production. Further described herein are, Di-IgG-encoding nucleic acids and vectors, host cells for making Di-IgGs, Di-IgG pharmaceutical compositions, and methods of treatment.

Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Abstract: The invention relates to monomeric Fc polypeptides and methods of making and using such polypeptides. The polypeptides comprise substitution of one or more hydrophobic interface residues in the CH3 region with a polar amino acid.